RevealDx: Seattle AI Profile — Product, Footprint & Verified Record

Modern Seattle computational biology and life-sciences research laboratory overlooking Pacific Northwest evergreens

About Will

I run Tygart Media, an AI-first agency that gets businesses cited and recommended by AI assistants — and I write about what we do, including what breaks.

Connect on LinkedIn →
Washington AI Companies Census · Verified Record (November 19, 2026)
Sourced Baseline: As of November 19, 2026, RevealDx operates as an independent, privately held Seattle clinical AI company headquartered on Westlake Avenue North with approximately 9 employees tracked by PitchBook. Following U.S. FDA 510(k) clearance in February 2026 and an August 2026 US$3.4M Series A led by strategic partner 4DMedical (which holds a 10% stake and distribution rights), RevealDx is scaling commercial deployment of RevealAI-Lung across U.S., European, and Australian radiology markets. Cumulative venture funding ranges from ~$7.85M in PitchBook tracking to $12M+ across longer corporate history reported by GeekWire.
PROFILE BRIEF · HOUSE PDF & MARKDOWN TWIN
RevealDx — Seattle AI Profile
Download the formatted 2-page profile brief (PDF) or open the single-source Markdown twin for RevealDx. Every claim below links to its verified primary source.

What RevealDx Builds

RevealDx develops RevealAI-Lung, a U.S. FDA 510(k)-cleared (K251769) computer-aided diagnostic (CADx) AI software application designed to analyze radiomic digital biomarkers on chest CT scans. Its clinical purpose, detailed on the RevealDx official website, is to assist radiologists in distinguishing benign pulmonary nodules from lung cancer earlier in the evaluation workflow.

The software computes a continuous Malignancy Similarity Index (mSI™) score from 0 to 1—grouped into low, intermediate, and high risk bands. In the United States, RevealAI-Lung and its mSI™ score are cleared for evaluating incidentally-detected pulmonary nodules measuring 6–15 mm in diameter in patients aged 18 and older, and are explicitly not indicated for routine lung cancer screening in the U.S.

  • FDA 510(k)-Cleared CADx Software: Cleared under K251769 (announced February 2026) for incidentally-detected pulmonary nodules measuring 6–15 mm in adults 18 and older.
  • Malignancy Similarity Index (mSI™): Outputs a continuous 0-to-1 radiomics score categorized into low, intermediate, and high malignancy risk bands.
  • Multi-Region Regulatory Status: Holds European MDR certification (November 2025) and Australian TGA approval in addition to U.S. FDA 510(k) clearance.
  • Reimbursement Pathways: Supported in the U.S. by Medicare reimbursement CPT codes 0721T and 0722T.
RevealDx — Verified Washington AI Snapshot
Verified profile snapshot for RevealDx (Seattle, WA) as of November 19, 2026.
FieldVerified Record (As of Nov 19, 2026)
CompanyRevealDx
Official Websitehttps://www.reveal-dx.com/
Washington HQSeattle, WA (1800 Westlake Ave. N, Suite 104, Seattle, WA 98109)
Other WA Footprint2026 GeekWire Awards Innovation Finalist; backed by Pacific Northwest angel networks Alliance of Angels and Frontier Angels
Founded2021 (reorganized from Mindshare Medical, founded 2014)
Founders / LeadershipChris Wood (CEO), Michael Calhoun (CTO), Dr. Ryan Brevard (Director of Clinical Programs), David Austin (VP of Sales)
StageSeries A
Announced Funding~$7.85M–$12M+ (includes Aug 2026 US$3.4M / A$4.9M Series A led by 4DMedical)
Team Size~9 (PitchBook)
Primary Ecosystem TiesSeattle Westlake HQ, Alliance of Angels & Frontier Angels (investors), 2026 GeekWire Awards Innovation Finalist

Washington Footprint and Leadership

RevealDx is headquartered along Lake Union at 1800 Westlake Ave. N, Suite 104, Seattle, WA 98109, with roughly 9 employees recorded by PitchBook. Its corporate history reflects two distinct milestones: CTO Michael Calhoun founded predecessor company Mindshare Medical in 2014 to develop the underlying lung-nodule radiomics technology, before the business was acquired and reorganized under Precision Medical Ventures in 2021 to operate as RevealDx under CEO Chris Wood, as outlined on the RevealDx Company page and in GeekWire's 2024 coverage.

As regulatory clearances converted into active commercial rollout in late 2026, the company expanded its clinical and go-to-market bench. On November 2, 2026, RevealDx announced via its November 2026 leadership press release the appointments of Dr. Ryan Brevard (previously a Medical Advisor) as Director of Clinical Programs and medtech executive David Austin as Vice President of Sales.

  • Seattle Westlake Office: Operating from 1800 Westlake Ave. N, Suite 104, Seattle, WA 98109.
  • Corporate Continuity: Reorganized in 2021 under Precision Medical Ventures from predecessor Mindshare Medical, founded in 2014 by CTO Michael Calhoun.
  • Commercial & Clinical Expansion: Appointed Dr. Ryan Brevard (Director of Clinical Programs) and David Austin (VP of Sales) on November 2, 2026.
  • Local Ecosystem Recognition: Named an Innovation finalist at the 2026 GeekWire Awards and backed by Pacific Northwest angel groups Alliance of Angels and Frontier Angels.
Aerial view of the Greater Seattle and Bellevue Lake Washington technology corridor with Mount Rainier on the horizon
Washington AI ecosystem context: Aerial view of the Greater Seattle and Bellevue Lake Washington technology corridor with Mount Rainier on the horizon.

Products, Users, and Public Traction

RevealDx builds for radiologists, hospital lung nodule programs, health systems, and clinical imaging providers managing incidental CT findings. Rather than selling solely through a small direct sales team, the company has assembled clinical workflow integrations and distribution partnerships tracked in the RevealDx Press Room. Key partners include Azra AI (a May 2026 partnership integrating RevealAI-Lung nodule characterization into Azra's oncology workflow and incidental findings platform), technical integrations with Riverain Technologies and Fuji PACS, U.S. distributor Sirona, and global distributor 4DMedical.

In clinical validation cited on the RevealDx official website, the company's clearance reader study on size-matched nodules smaller than 8 mm reported that ten radiologists improved diagnostic accuracy from an unaided AUC of 0.459 to 0.728 with mSI™ assistance, while retrospective validation across more than 1,500 diagnosed cases indicated mSI™ would have accelerated follow-up in 45% (range 33–59%) of guideline-deferred cancers. RevealDx is also exhibiting at RSNA 2026 (November 29–December 2, 2026, South Hall AI Showcase Booth 5930).

  • Global Distribution via 4DMedical: Under its August 2026 distribution agreement, 4DMedical holds exclusive distribution rights in Europe, Australia, and New Zealand and non-exclusive rights in the U.S.
  • Workflow & PACS Integrations: Partnered with Azra AI (May 2026) for incidental oncology workflow automation, alongside Riverain Technologies, Fuji PACS, and U.S. distributor Sirona.
  • Clearance Reader Study Metrics: RevealDx reports unaided radiologist accuracy on sub-8 mm nodules improved from AUC 0.459 to 0.728 with mSI™ support.
  • RSNA 2026 Presence: Scheduled to exhibit RevealAI-Lung at RSNA 2026 in Chicago from November 29 through December 2, 2026.

Funding, Stage, and Place in Washington's AI Landscape

In August 2026, Melbourne-based respiratory imaging company 4DMedical led RevealDx's Series A with a US$3.4M (A$4.9M) strategic investment. As disclosed in the 4DMedical partnership announcement, the financing gave 4DMedical a 10% fully diluted equity stake, one board seat, and a right of first negotiation over any future sale, while leaving RevealDx an independent, privately held Seattle corporation.

Across data providers, total disclosed venture funding for RevealDx spans a range from approximately $7.85M in PitchBook records to $12M+ when incorporating cumulative historical funding reported by GeekWire across its earlier rounds (including a $4.2M raise covered by GeekWire in 2024). Backed by A-Level Capital, Alliance of Angels, Frontier Angels, Frost Data Capital, Life Science Angels, and 4DMedical, RevealDx stands out in Washington's health AI cohort for pairing regulated FDA 510(k) and EU MDR clearances with established CPT reimbursement codes on a lean capital base.

  • Strategic Series A Lead: 4DMedical led the August 2026 US$3.4M (A$4.9M) Series A, taking a 10% equity stake, a board seat, and a right of first negotiation on a future sale.
  • Cumulative Funding Range: Reported venture totals span ~$7.85M (PitchBook) to $12M+ (cumulative GeekWire history across predecessor and reorganized rounds).
  • Angel & Institutional Syndicate: Investors include 4DMedical, A-Level Capital, Alliance of Angels, Frontier Angels, Frost Data Capital, and Life Science Angels.
  • Regulated Clinical Differentiation: Combines FDA 510(k), EU MDR, TGA approval, and Medicare CPT codes 0721T/0722T within a compact Seattle medtech team.

Related Washington AI Profiles & Tygart Media Context

Verified Primary Sources

Get The Signal

What we actually ran, what it measured, and what it means for a restoration shop — every week, including the flops.

Subscription Form

Track the AI tools you actually use
Vendor-neutral prices & limits for ChatGPT, Claude, Gemini, Perplexity and more — tracked in AI Stack Watch.
See the live AI tracker →or set up your alerts

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *